

Janssen Pharmaceutical Companies of Johnson & Johnson

Selected Novel Therapies - Recent Approvals/Potential Filings*

(2021-2025 Key Filings, As Outlined at 2021 Pharm Business Review)

Selective Highlights as of January 24, 2023

Novel Therapies APPROVED	Novel Therapies in REGISTRATION	Novel Therapies PLANNED FILINGS	
Oncology RYBREVANT (amivantamab) Non Small Cell Lung Cancer	Oncology niraparib EU Metastatic castration-resistant prostate cancer (mCRPC)	Cardiovascular and Metabolism RPGR AAV Gene Therapy X-linked retinitis pigmentosa	Neuroscience seltorexant Adjunctive treatment for major depressive disorder with insomnia
CARVYKTI (Ciltacabtagene autoleucel) Relapsed refractory Multiple Myeloma	talquetamab (GPCR5D/CD3) Multiple myeloma	aprocitentan EU Difficult to treat hypertension	Aticaprant Adjunctive treatment for major depressive disorder
teclistamab (BCMA/CD3) Relapsed refractory Multiple Myeloma	Cardiovascular and Metabolism US aprocitentan Difficult to treat hypertension	Infectious Diseases and Vaccines RSV Adult Vaccine RSV vaccine	nipocalimab Generalized Myasthenia Gravis
		JNJ-3989 siRNA HBV/HDV Co-infection	Oncology TAR-200 (RIS/gemcitabine) Bladder Cancer
		Immunology Oral IL-23i Psoriasis	US niraparib Metastatic castration-resistant prostate cancer (mCRPC)
			Pulmonary Hypertension Macitentan 75mg Chronic thromboembolic pulmonary hypertension



Filings/approvals assumed to be in the US and EU unless otherwise noted. This information is accurate as of the date hereof to the best of the Company's knowledge. Johnson & Johnson assumes no obligation to update this information. BALVERSA discovered in collaboration with Astex Pharmaceuticals, Inc.; Niraparib licensed from Tesaro; BCMA CAR-T licensed from Legend Biotech; Monovalent Ebola Vaccine developed in collaboration with Bavarian Nordic A/S, and MVA-BN-Filo® is licensed-in from Bavarian Nordic A/S; DUOBODY platform licensed from Genmab relates to several bispecific antibody programs (Amivantamab, Teclistamab, Talquetamab); Lazertinib licensed from Yuhan Corporation; Retinal assets (Achromatopsia: AAV-CNGA3, AAV-CNGB3) and (X-Linked Retinitis Pigmentosa: AAV-RPGR) licensed from MeiraGTx;